Drug Profile

AMTX 036

Alternative Names: AMTX-036; KDT-501

Latest Information Update: 28 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator KinDex Pharmaceuticals
Developer Amaro Therapeutics; KinDex Pharmaceuticals
Class Alkanes; Anti-inflammatories; Antihyperglycaemics; Cyclopentanes; Esters; Ketones; Obesity therapies; Small molecules
Mechanism of Action TAS2R1 protein agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Preclinical Obesity
Discontinued Inflammation; Non-alcoholic steatohepatitis; Polycystic ovary syndrome; Type 2 diabetes mellitus

28 May 2025 Discontinued - Preclinical for Polycystic ovary syndrome in USA (PO), before May 2025 (Amaro Therapeutics website, May 2025)
28 May 2025 Preclinical trials in Obesity in USA (PO), before May 2025 (Amaro Therapeutics website, May 2025)
27 May 2022 Discontinued - Preclinical for Inflammation in USA (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com